Author:
Y. Shan Frank,Feng Dongxia,Zhang Yilu,Fung Karming,H. Murillo Jennifer,H. Huang Jason
Abstract
Meningiomas are the most common primary brain tumors in adults. They are slow growing, mostly benign tumors affecting primarily older people. Meningiomas comprise a family of neoplasms that are most likely derived from the meningothelial cells of the arachnoid cap cell. Current diagnosis of meningioma has been facilitated by MRI scans, and most patients with meningiomas have good prognosis without affecting the quality of life after successful treatment, like gross total resection (GTR). This chapter will briefly review the molecular basis, clinical diagnosis and grading of meningiomas and the treatment options.
Reference11 articles.
1. International Agency for Research on Cancer. WHO Classification of Tumours, Editorial Board, Central Nervous System Tumours. 5th ed. Lyon, France: International Agency for Research on Cancer; 2021
2. Perry A, Stafford SL, Scheithauer BW, Suman VJ, Lohes CM. Meningioma grading: An analysis of histologic parameters. American Journal of Surgical Pathology. 1997;(12):1455-1465
3. Davidson C. Histopathologic and molecular evaluation of meningioma. Neurosurgery Clinics of North America. 2023;:311-318
4. Sahm F, Schrimpf D, et al. DNA-methylation-based classification and grading system for meningioma: A multicentre, retrospective analysis. The Lancet Oncology. 2017;:682-694
5. Shoh S, Maiko T, Takanori H, Tomomi F, Hiroe I, Tomoko U, et al. Correlation of MTAP immuno-histochemistry with CDKN2A status assessed by fluorescence In situ hybridization and Clinicopathological features in CNS WHO grade 2 and 3 Meningiomas: A single Center cohort study. Journal of Neuropathology and Experimental Neurology. 2022;(2):117-126